Veos Pharmaceuticals Wins Third Prize at the 9th China (Shenzhen) International Innovation & Entrepreneurship Competition and Advances to Industrial Phase in Shenzhen
Recognition highlights ThymoTropin™ as Veos Pharma's breakthrough natural dual-action myostatin inhibitor and TRPV3 activator.
Madrid, Spain — October 30, 2025 — Veos Pharmaceuticals S.L., a Spain-based biotechnology company pioneering natural innovations for health and sustainability, has won Third Prize at the 9th China (Shenzhen) International Innovation & Entrepreneurship Competition (IEIC) — Barcelona Division — and has been selected to advance to the Industrial Phase in Shenzhen, China.
The recognition highlights ThymoTropin™, Veos Pharma's breakthrough natural dual-action myostatin inhibitor and TRPV3 activator, a clinically validated, non-hormonal innovation that enhances muscle strength, endurance, and metabolic health. ThymoTropin™ addresses muscle loss associated with aging, GLP-1 treatments, and chronic disease — positioning Veos as a global leader in muscle health biotechnology.
"Being recognized among the top three companies and moving forward to the Shenzhen industrial phase represents a major milestone for Veos. It validates our vision of bringing scientifically proven, sustainable solutions from Spain to the global market — from health to agriculture and environmental biotechnology." — Dr. Bassam Damaj, CEO and Co-Founder of Veos Pharmaceuticals
The Shenzhen Industrial Phase will provide Veos with access to strategic investors, industrial partners, and Chinese market expansion opportunities, supporting the company's plan to scale ThymoTropin™ and other Veos technologies across Asia.
"These are exactly the type of high-performing assets we look for: established, profitable, and trusted by consumers. By integrating SSD's portfolio into our broader consumer-health platform, we will preserve each brand's market strength and unlock additional scale through our data-driven supply chain and marketing infrastructure." — Samira Wifak, Managing Partner at Veos Ventures
Expected Financial Contribution
The acquisition is expected to be immediately accretive to Veos' 2025 financial performance.
Projected first-year ROI is above 50%, driven by marketing efficiencies, improved logistics, and operational consolidation between Veos Pharma's European and Canadian e-commerce systems.
net sales
first-year ROI
Amazon brands
Upon completion, Veos will assume full operational control of the Canadian Amazon accounts, trademarks, and inventory.
About Veos Pharmaceuticals
Veos Pharmaceuticals S.L. is a Madrid-based specialty healthcare and consumer-wellness company focused on developing, acquiring, and marketing scientifically validated natural health solutions and OTC medical products. Veos operates across Europe and North America through a growing portfolio of direct-to-consumer brands.
Its product ecosystem includes leading natural-health and OTC brands such as ThymoTropin™, StroVia™, OleoSorb™, VEOX-Preserve™, and a growing suite of Amazon-native wellness and pet-care products.
For more information, visit www.veospharma.com.
Media & Investor Contact
Veos Pharmaceuticals, S.L.
Calle Núñez de Balboa, 35 A-5 Planta Oficina A1
28001 Madrid, Spain
Email: info@veospharma.com
Telephone: +34 911 925 649
Website: www.veospharma.com